Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - . short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesphagitis. the intravenous injection is indicated where oral treatment is inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium benzoate; povidone; sodium bicarbonate; monosodium dihydrogen citrate; aspartame; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. new indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short- term symptomatic treatment of reflux oe

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 16.8 mg/ml (equivalent: ranitidine, qty 15 mg/ml) - oral liquid - excipient ingredients: hypromellose; ethanol; sorbitol solution (70 per cent) (non-crystallising); butyl hydroxybenzoate; saccharin sodium; propyl hydroxybenzoate; sodium chloride; dibasic sodium phosphate; monobasic potassium phosphate; purified water; flavour - short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage: maintenance treatment to reduce the risk of relapse in duodenal ulcer: maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer: treatment of gastrinoma (zollinger-ellison syndrome): short-term treatment of severe reflux oesophagitis: treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate. new indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrom

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 28 mg/ml (equivalent: ranitidine, qty 25 mg/ml) - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride - indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids.indications as at 11 february 2005: 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ranitidine hydrochloride 28 mg/ml equivalent to ranitidine 25 mg/ml;   - solution for injection - 50mg/2ml - active: ranitidine hydrochloride 28 mg/ml equivalent to ranitidine 25 mg/ml   excipient: dibasic sodium phosphate monobasic potassium phosphate sodium chloride water for injection - zantac injection is indicated for the short-term treatment of duodenal ulcer, benign gastric ulcer, post-operative ulcer, reflux oesophagitis, zollinger-ellison syndrome, and the following conditions where a reduction of gastric secretion and acid output is desirable: the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers and before general anaesthesia in patients considered to be at risk of acid aspiration (mendelson's) syndrome, particularly obstetric patients during labour.

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - zantac injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication. zantac injection is contraindicated for patients known to have hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

teligent, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 25 mg in 1 ml - zantac injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication. zantac injection is contraindicated for patients known to have hypersensitivity to the drug.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ranitidine hydrochloride 16.8 mg/ml equivalent to ranitidine 15 mg/ml;   - syrup - 150mg/10ml - active: ranitidine hydrochloride 16.8 mg/ml equivalent to ranitidine 15 mg/ml   excipient: butyl hydroxybenzoate dibasic sodium phosphate ethanol hypromellose mint flavour 17.42.3632 monobasic potassium phosphate propyl hydroxybenzoate saccharin sodium sodium chloride sorbitol water - -the treatment of duodenal ulcer, and benign gastric ulcer, including that associated with non-steroidal anti- inflammatory agents. - the prevention of non-steroidal anti-inflammatory agent (including aspirin) associated duodenal ulcers in patients with a history of duodenal ulceration proven by endoscopy. - the treatment of post-operative ulcer - the treatment of oesophageal reflux disease - symptom relief in gastro-oesophageal reflux disease - the treatment of zollinger-ellison syndrome - the treatment of chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but not associated with the above conditions. zantac syrup is also indicated for the following conditions where reduction of gastric secretion and acid output is desirable: - the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patients. - the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers. - before general anaesthesia in patients considered to be at risk of acid aspiration (mendelson's syndrome), particularly obstetric patients during labour.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains ranitidine hydrochloride equivalent to 150 mg ranitidine